The foundation and architecture of precision medicine in neurology and psychiatry
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Neurological and psychiatric diseases have high degrees of genetic and pathophysiological heterogeneity, irrespective of clinical manifestations. Traditional medical paradigms have focused on late-stage syndromic aspects of these diseases, with little consideration of the underlying biology. Advances in disease modeling and methodological design have paved the way for the development of precision medicine (PM), an established concept in oncology with growing attention from other medical specialties. We propose a PM architecture for central nervous system diseases built on four converging pillars: multimodal biomarkers, systems medicine, digital health technologies, and data science. We discuss Alzheimer's disease (AD), an area of significant unmet medical need, as a case-in-point for the proposed framework. AD can be seen as one of the most advanced PM-oriented disease models and as a compelling catalyzer towards PM-oriented neuroscience drug development and advanced healthcare practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 1×
“A similar initiative in the UK, the UK Biobank, has created a robust biomedical database that can be accessed globally by different stakeholders for clinical and public health research [183].”
Complex brain networks: graph theoretical analysis of structural and functional systems
Bullmore, E., & Sporns, O. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2575 · Cited by 11,820 · cited 2×
“In the past two decades, graph theoretical measures applied to neuroimaging have revealed abnormalities of network configurations in clinically defined pathological conditions [89].”
Complex network measures of brain connectivity: Uses and interpretations
Rubinov, M., & Sporns, O. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.003 · Cited by 11,522
Rudin, C. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0048-x · Cited by 10,561 · cited 2×
“A related point is that AI methods may reveal systems complexity; while recognizing this complexity is an essential step towards understanding the disease state(s) and the compensation to incipient dynamics that prevent systems failure, current AI approaches are limited in elucidating how or why complexity arises, thu…”
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Machine learning: Trends, perspectives, and prospects
Jordan, M. I., & Mitchell, T. M. (2015) · Science · doi:10.1126/science.aaa8415 · Cited by 9,955 · cited 13×
“The resulting clusters or latent dimensions of variation can in turn reveal the latent, long-postulated biological heterogeneity underlying the symptoms that may influence treatment response and clinical–biological trajectories [131,135].”
InfluentialMDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
The global landscape of AI ethics guidelines
Jobin, A., Ienca, M., & Vayena, E. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0088-2 · Cited by 6,220
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034 · cited 2×
“Critical biological factors whose perturbation may lead to systems failure can be uncovered by computational analysis of large, multidimensional datasets under the systems-network theory [86–88].”
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“At this point, homeostasis, with the underlying core biological feedback loops and networks and systems have been overwhelmed and begin to break down at varying points along the spatial and temporal continuum with decompensation and subsequent system failure in an individual manner [16,17].”
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 1×
“, Aβ and tau), depending on disease stages and individual susceptibility [156,157].”
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · cited 1×
“are in development programs aligned with this approach, such as larotrectinib for TRK fusion-positive cancers [188].”
Estimating the true global burden of mental illness
Vigo, D., Thornicroft, G., & Atun, R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00505-2 · Cited by 2,494
The “All of Us” Research Program
The All of Us Research Program Investigators (2019) · New England Journal of Medicine · doi:10.1056/nejmsr1809937 · Cited by 2,440 · cited 3×
“Screening represents the most effective strategy for risk prediction and early detection/disease prevention [182].”
InfluentialResting-state connectivity biomarkers define neurophysiological subtypes of depression
Drysdale, A. T., Grosenick, L., Downar, J., Dunlop, K., Mansouri, F., Meng, Y., Fetcho, R. N., Zebley, B., Oathes, D. J., Etkin, A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4246 · Cited by 2,170 · cited 4×
“This approach could be applied to AD, other neurodegenerative diseases, and a spectrum of affective disorders [78,136–139].”
InfluentialInternational Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864 · cited 1×
“This has led to the conceptualization of a symptom-agnostic, biomarker-based classification system called the Amyloid-β/Tau/Neurodegeneration [AT(N)] system, which stratifies individuals upon core pathophysiological changes in AD [154].”
Self-citationCurrent and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557 · cited 2×
“, liquid biopsy) [185], to guide diagnostic and therapeutic”
Polygenic risk scores: from research tools to clinical instruments
Lewis, C. M., & Vassos, E. (2020) · Genome Medicine · doi:10.1186/s13073-020-00742-5 · Cited by 1,360
Personal omics profiling reveals dynamic molecular and medical phenotypes
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y. K., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.009 · Cited by 1,291
Glymphatic failure as a final common pathway to dementia
Nedergaard, M., & Goldman, S. A. (2020) · Science · doi:10.1126/science.abb8739 · Cited by 1,145 · cited 1×
“At this point, homeostasis, with the underlying core biological feedback loops and networks and systems have been overwhelmed and begin to break down at varying points along the spatial and temporal continuum with decompensation and subsequent system failure in an individual manner [16,17].”
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
Garrett-Bakelman, F. E., Darshi, M., Green, S. J., Gur, R. C., Lin, L., Macias, B. R., McKenna, M. J., Meydan, C., Mishra, T., Nasrini, J., et al. (2019) · Science · doi:10.1126/science.aau8650 · Cited by 1,128 · cited 1×
“Epigenomics, the systematic investigation of nonmutational gene expression patterns within the genome, provides a means to systematically explore the effects of gene–exposome interaction [51].”
The genetic architecture of Parkinson's disease
Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30287-x · Cited by 1,114
Systems Biology and New Technologies Enable Predictive and Preventative Medicine
Hood, L., Heath, J. R., Phelps, M. E., & Lin, B. (2004) · Science · doi:10.1126/science.1104635 · Cited by 1,108 · cited 1×
“According to the concepts in systems biology, physiological functions and pathophysiological changes may be mapped along highly connected networks of genes/ proteins/metabolites/lipids with critical connection and intersection [49,53,85,90,91].”
Firth, J., Torous, J., Nicholas, J., Carney, R., Pratap, A., Rosenbaum, S., & Sarris, J. (2017) · World Psychiatry · doi:10.1002/wps.20472 · Cited by 1,097 · cited 1×
“In addition, digital technologies are being explored as therapeutics [129].”
Drug discovery with explainable artificial intelligence
Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00236-4 · Cited by 1,063 · cited 1×
“Although significant progress has been made recently, various challenges, including the need for explainability and trustworthiness [147], hinder the AI-scaled transformation of medicine and neurology.”
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045 · cited 1×
“Summarizing advances in this evolving area would be beyond the scope of the current article and we refer readers to recent review articles that have addressed the topic, particularly in the context of neurodegenerative disorders [66–68].”
A deep learning framework for neuroscience
Richards, B. A., Lillicrap, T. P., Beaudoin, P., Bengio, Y., Bogacz, R., Christensen, A., Clopath, C., Costa, R. P., de Berker, A., Ganguli, S., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0520-2 · Cited by 1,027 · cited 1×
“The resulting clusters or latent dimensions of variation can in turn reveal the latent, long-postulated biological heterogeneity underlying the symptoms that may influence treatment response and clinical–biological trajectories [131,135].”
Sex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009 · cited 5×
“Such an apparent predisposition of females to AD is not influenced by age itself, thus reinforcing the hypothesis that hormonal factors, some of them linked to menopause, may play a critical role [153,174].”
InfluentialSelf-citationJohnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001 · cited 3×
“Proteomics has been widely used to identify the ultimate pathophysiological mechanisms as well as to develop, validate, and qualify bodily fluid biomarkers in AD, PD, and schizophrenia [56–58].”
Large-scale physical activity data reveal worldwide activity inequality
Althoff, T., Sosič, R., Hicks, J. L., King, A. C., Delp, S. L., & Leskovec, J. (2017) · Nature · doi:10.1038/nature23018 · Cited by 1,000 · cited 1×
“information databases via digital technologies, such as wearable devices, smartphones, and edge computing [181].”
Comprehensive functional genomic resource and integrative model for the human brain
Wang, D., Liu, S., Warrell, J., Won, H., Shi, X., Navarro, F. C. P., Clarke, D., Gu, M., Emani, P., Yang, Y. T., et al. (2018) · Science · doi:10.1126/science.aat8464 · Cited by 965 · cited 1×
“For example, genomic, tissue-level and single-cell transcriptomics and epigenetic data have been integrated to identify gene regulatory networks in the brain and predict endo- and syndromic phenotypes of psychiatric disorders [97].”
Hansen, J. Y., Shafiei, G., Markello, R. D., Smart, K., Cox, S. M. L., Nørgaard, M., Beliveau, V., Wu, Y., Gallezot, J.-D., Aumont, É., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01186-3 · Cited by 797 · cited 1×
“of these patterns to cell-specific gene expression patterns and to neuroreceptor distributions [114], implicating specific cell types and molecular pathways in psychiatric”
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01309-6 · Cited by 741 · cited 1×
“This approach could be applied to AD, other neurodegenerative diseases, and a spectrum of affective disorders [78,136–139].”
Jo, T., Nho, K., & Saykin, A. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00220 · Cited by 724
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716 · cited 1×
“cost-, resource-, and time effective [67].”
Self-citationCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud, A. M., Zotti, R. J., Shehzad, Z., Gueorguieva, R., Johnson, M. K., Trivedi, M. H., Cannon, T. D., Krystal, J. H., & Corlett, P. R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00471-x · Cited by 676 · cited 1×
“In clinical trials, unsupervised algorithms trained on clinical or biomarker data have already been shown to predict treatment response in depression and AD [142,143].”
CSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30024-9 · Cited by 673 · cited 1×
“Summarizing advances in this evolving area would be beyond the scope of the current article and we refer readers to recent review articles that have addressed the topic, particularly in the context of neurodegenerative disorders [66–68].”
Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., & Davatzikos, C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.03.057 · Cited by 622
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases
Myszczynska, M. A., Ojamies, P. N., Lacoste, A. M. B., Neil, D., Saffari, A., Mead, R., Hautbergue, G. M., Holbrook, J. D., & Ferraiuolo, L. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0377-8 · Cited by 595 · cited 1×
“Computational models based on artificial intelligence (AI) approaches can generate clinically meaningful readouts using sparse and noisy multidimensional data from different sources [130].”
Metabolomics enables precision medicine: “A White Paper, Community Perspective”
for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative, Beger, R. D., Dunn, W., Schmidt, M. A., Gross, S. S., Kirwan, J. A., Cascante, M., Brennan, L., Wishart, D. S., Oresic, M., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1094-6 · Cited by 592
Schwartzentruber, J., Cooper, S., Liu, J. Z., Barrio-Hernandez, I., Bello, E., Kumasaka, N., Young, A. M. H., Franklin, R. J. M., Johnson, T., Estrada, K., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00776-w · Cited by 532 · cited 1×
“In this regard, crosstalks between the periphery and CNS have been reported in the context of the immune and inflammatory responses, lipid and glucose metabolism, and functional regulation of the glymphatic and blood–brain barrier systems [34,35,39].”
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationA Longitudinal Big Data Approach for Precision Health
Schüssler-Fiorenza Rose, S. M., Contrepois, K., Moneghetti, K. J., Zhou, W., Mishra, T., Mataraso, S., Dagan-Rosenfeld, O., Ganz, A. B., Dunn, J., Hornburg, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0414-6 · Cited by 494 · cited 2×
“As a next step, big data science approaches could facilitate the development of these multimodal biomarker variables [50] to support PM-oriented, individualized, stage-dependent treatments for older individuals who suffer from age-related diseases.”
Drug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
Seyfried, N. T., Dammer, E. B., Swarup, V., Nandakumar, D., Duong, D. M., Yin, L., Deng, Q., Nguyen, T., Hales, C. M., Wingo, T., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2016.11.006 · Cited by 477
Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity
Kourtis, L. C., Regele, O. B., Wright, J. M., & Jones, G. B. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0084-2 · Cited by 476 · cited 3×
“They also open new possibilities for longitudinal data collection and have the potential to provide useful information on prognosis and disease progression [118].”
Genetics and genomics of psychiatric disease
Geschwind, D. H., & Flint, J. (2015) · Science · doi:10.1126/science.aaa8954 · Cited by 424 · cited 1×
“For the vast majority of patients, genetic risk reflects the cumulative impact of common genetic variants that individually exert a small effect on disease susceptibility [27,28,33].”
Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387 · cited 1×
“During the preclinical stages of these diseases, genetic, environmental, and stochastic factors trigger and drive aberrant biological pathways that unfold at different rates across genetic-, epigenetic-, molecular-, cellular-, tissue-, and macro-scale networks, while relevant physiological functions exhibit only subtl…”
Automatic speech analysis for the assessment of patients with predementia and Alzheimer's disease
König, A., Satt, A., Sorin, A., Hoory, R., Toledo‐Ronen, O., Derreumaux, A., Manera, V., Verhey, F., Aalten, P., Robert, P. H., et al. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.012 · Cited by 380 · cited 1×
“Automated speech analysis is one promising method to detect mild cognitive impairment [161], although clinical validity in this context remains to be further tested.”
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360 · cited 2×
“The temporal-spatial dynamics of the neuroinflammatory process could be dissected through multi-omics profiling along with neuroimaging and could potentially be targeted by specific and stage-guided immune-modulator drugs, such as TREM2 agonists, to modify disease progression [157,158].”
Self-citationSex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau
Hohman, T. J., Dumitrescu, L., Barnes, L. L., Thambisetty, M., Beecham, G., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., Mukherjee, S., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0821 · Cited by 340
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I. E., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22491-8 · Cited by 324
Self-citationA small number of abnormal brain connections predicts adult autism spectrum disorder
Yahata, N., Morimoto, J., Hashimoto, R., Lisi, G., Shibata, K., Kawakubo, Y., Kuwabara, H., Kuroda, M., Yamada, T., Megumi, F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11254 · Cited by 305 · cited 1×
“, ASD) from typically developing controls [80] and predicting an individual’s response to treatment in various mental disorders (e.”
Lipsmeier, F., Taylor, K. I., Kilchenmann, T., Wolf, D., Scotland, A., Schjodt‐Eriksen, J., Cheng, W., Fernandez‐Garcia, I., Siebourg‐Polster, J., Jin, L., et al. (2018) · Movement Disorders · doi:10.1002/mds.27376 · Cited by 266 · cited 1×
“, motion, gait, pace, sleep, speech and voice patterns) [119,120].”
The human connectome in Alzheimer disease — relationship to biomarkers and genetics
Yu, M., Sporns, O., & Saykin, A. J. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00529-1 · Cited by 265 · cited 5×
“Such activity and neuroanatomical changes, described initially at the regional level and more recently also in terms of network modular organization, may ultimately allow prediction of long-term cognitive, behavioral, and functional outcomes even in cognitively healthy individuals at risk for AD [5,112,151].”
InfluentialZulueta, J., Piscitello, A., Rasic, M., Easter, R., Babu, P., Langenecker, S. A., McInnis, M., Ajilore, O., Nelson, P. C., Ryan, K., et al. (2018) · Journal of Medical Internet Research · doi:10.2196/jmir.9775 · Cited by 233 · cited 1×
“…other wearable analytics, and smart technologies are under development to support early detection and management of different behavioral and psychological symptoms, such as psychosis, changes in mood, and circadian rhythm disruption, in several neurological and psychiatric conditions [125–128].”
Time to reality check the promises of machine learning-powered precision medicine.
Wilkinson, J., Arnold, K. F., Murray, E. J., van Smeden, M., Carr, K., Sippy, R., de Kamps, M., Beam, A., Konigorski, S., Lippert, C., et al. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30200-4 · Cited by 233 · cited 2×
“Analysis of EHR databases with AI has augmented diagnosis, prognosis, and prediction of disease onset or progression to better inform clinical decision-making [144].”
Brain connectomics predict response to treatment in social anxiety disorder
Whitfield-Gabrieli, S., Ghosh, S. S., Nieto-Castanon, A., Saygin, Z., Doehrmann, O., Chai, X. J., Reynolds, G. O., Hofmann, S. G., Pollack, M. H., & Gabrieli, J. D. E. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.109 · Cited by 210
Sex differences in movement disorders
Meoni, S., Macerollo, A., & Moro, E. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0294-x · Cited by 207
A Solution-Focused Research Approach to Achieve an Implementable Revolution in Digital Mental Health
Mohr, D. C., Riper, H., & Schueller, S. M. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3838 · Cited by 204
Wang, M., Li, A., Sekiya, M., Beckmann, N. D., Quan, X., Schrode, N., Fernando, M. B., Yu, A., Zhu, L., Cao, J., et al. (2021) · Neuron · doi:10.1016/j.neuron.2020.11.002 · Cited by 185
Genetics of schizophrenia: new findings and challenges
Gejman, P. V., Sanders, A. R., & Kendler, K. S. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101459 · Cited by 183 · cited 1×
“This includes monogenic forms of AD or frontotemporal dementia [27], PD and other movement disorders [28,29], ALS and other motoneuron disorders, schizophrenia [30], and ASD [31].”
Zhao, P., Xu, Y., Jiang, L., Fan, X., Li, L., Li, X., Arase, H., Zhao, Y., Cao, W., Zheng, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0095 · Cited by 141 · cited 1×
“The temporal-spatial dynamics of the neuroinflammatory process could be dissected through multi-omics profiling along with neuroimaging and could potentially be targeted by specific and stage-guided immune-modulator drugs, such as TREM2 agonists, to modify disease progression [157,158].”
Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s disease
Ping, L., Kundinger, S. R., Duong, D. M., Yin, L., Gearing, M., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2020) · Scientific Data · doi:10.1038/s41597-020-00650-8 · Cited by 127
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126 · cited 2×
“This includes monogenic forms of AD or frontotemporal dementia [27], PD and other movement disorders [28,29], ALS and other motoneuron disorders, schizophrenia”
Noori, A., Mezlini, A. M., Hyman, B. T., Serrano-Pozo, A., & Das, S. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105225 · Cited by 98 · cited 2×
“For instance, translational models of the neurodegenerative disease spectrum indicate a prominent role of inflammatory and immune responses in the pathophysiological process, and preclinical data support a potential role for anti-inflammatory treatments in AD and ALS, among others [10].”
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96 · cited 1×
“For instance, studies in AD suggest that the early preclinical stages have homeostatic and cellular adaption mechanisms that afford resilience to the incipient pathophysiological changes, a compensation mechanism that may be lost as the disease progresses [15].”
Hampel, H., Williams, C., Etcheto, A., Goodsaid, F., Parmentier, F., Sallantin, J., Kaufmann, W. E., Missling, C. U., & Afshar, M. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12013 · Cited by 84 · cited 1×
“In clinical trials, unsupervised algorithms trained on clinical or biomarker data have already been shown to predict treatment response in depression and AD [142,143].”
Self-citationHampel, H., Vergallo, A., Giorgi, F. S., Kim, S. H., Depypere, H., Graziani, M., Saidi, A., Nisticò, R., & Lista, S. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.06.001 · Cited by 68 · cited 1×
“The presence of sexual dimorphism in brain health and disease calls for reconsideration of treatment outcome assessments, taking sex-biased biological factors into account rather than treating sex as a simple covariate [153,175].”
Self-citationKlein, H.-U., Bennett, D. A., & De Jager, P. L. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1612-7 · Cited by 49
Vergallo, A., Houot, M., Cavedo, E., Lemercier, P., Vanmechelen, E., De Vos, A., Habert, M., Potier, M., Dubois, B., Lista, S., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.001 · Cited by 32 · cited 1×
“…AD of menopausal women relative to age-matched men has been linked by cross-disciplinary studies to higher risk of dysregulation of the A β and neuroinflammatory pathways, disruptions of the cholinergic nuclei of the basal forebrain, and failure of large-scale networks in the brain [153,170–173].”
Self-citationde Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2019) · doi:10.1101/19012021 · Cited by 28
Nature and implications of sex differences in AD pathology
Babapour Mofrad, R., & van der Flier, W. M. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0115-7 · Cited by 24 · cited 1×
“…AD of menopausal women relative to age-matched men has been linked by cross-disciplinary studies to higher risk of dysregulation of the A β and neuroinflammatory pathways, disruptions of the cholinergic nuclei of the basal forebrain, and failure of large-scale networks in the brain [153,170–173].”
Chang, M. C., Kwak, S. G., Park, J.-S., & Park, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-71813-1 · Cited by 17 · cited 1×
“Of note, clinical trials with non-steroidal anti-inflammatory drugs have failed to prove efficacy so far [11] (detailed examination of the potential factors accounting for the lack of success are beyond the scope of the discussion here).”
Cited by
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
“31,32 12 ARIA are MRI signal abnormalities that present as oedema/effusion (ARIA-E) or microhaemorrhage/superficial siderosis (ARIA-H).”
BackgroundSelf-citationHampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Self-citationRadiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“Its seamless integration of imaging and therapy, underpinned by precise radiotracer design and innovative instrumentation, holds the potential to reshape the landscape of medical practice, ultimately culminating in improved patient care and unprecedented medical breakthroughs [51].”
BackgroundHu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H. (2024) · Med · doi:10.1016/j.medj.2024.08.004 · Cited by 42
Self-citation
Metadata
- Authors
- Hampel, H., Gao, P., Cummings, J., Toschi, N., Thompson, P. M., Hu, Y., Cho, M., & Vergallo, A.
- Venue
- Trends in Neurosciences
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 46
- Issue
- 3
- Pages
- 176-198
- ISSN
- 0166-2236 (ISSN-L)
- OpenAlex
- W4315871740
- Cited by
- 143
- References
- 78
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.